ArticleThe Biochemical journal1994
Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation.
Article in The Biochemical journal, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 65 citations in OpenAlex.
- ANXA5: related mechanisms of osteogenesis and additional biological functions.Frontiers in cell and developmental biology · 2025Review
- Article
- The Relevance, Predictability, and Utility of Annexin A5 for Human Physiopathology.International journal of molecular sciences · 2024Review
- Therapeutic Potential of Annexins in Sepsis and COVID-19.Frontiers in pharmacology · 2021Review
- Multiple Origins of Secretagogin Expressing Cortical GABAergic Neuron Precursors in the Early Human Fetal Telencephalon.Frontiers in neuroanatomy · 2020Article
- An αThe Journal of biological chemistry · 2019Article
- Annexin A5 increases survival in murine sepsis model by inhibiting HMGB1-mediated pro-inflammation and coagulation.Molecular medicine (Cambridge, Mass.) · 2016Article
- Neuroprotective Effect of Resveratrol on Acute Brain Ischemia Reperfusion Injury by Measuring Annexin V, p53, Bcl-2 Levels in Rats.Journal of Korean Neurosurgical Society · 2015Article
- AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice.Journal of cellular and molecular medicine · 2014Article
- Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.Journal of biomedical science · 2014Article
- Article
- Apoptotic markers in protozoan parasites.Parasites & vectors · 2010Article
- Measurement of the binding parameters of annexin derivative-erythrocyte membrane interactions.Analytical biochemistry · 2010Article
- Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.Blood · 2006Article
- Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus.Journal of virology · 2004Article
- Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome.Clinical and experimental immunology · 2000Article
- Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.The Journal of clinical investigation · 1998Article
- Dissimilar interaction of factor VIII with endothelial cells and lipid vesicles during factor X activation.The Biochemical journal · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Annexin V binds with high affinity to procoagulant phospholipid vesicles and thereby inhibits the procoagulant reactions catalysed by these surfaces in vitro. In vivo, vascular endothelial cells are known to catalyse the formation of thrombin by the expression of binding sites at which procoagulant complexes can assemble. Here, we have studied the binding capacity of recombinant annexin V (rANV) to quiescent, phorbol 12-myristate 13-acetate (PMA)- and tumour necrosis factor alpha (TNF-alpha)-stimulated cultured human umbilical-vein endothelial cells (HUVEC). The dissociation constant (Kd) was 15.5 +/- 3.3 nM and the number of binding sites was 8.8 (+/- 3.9) x 10(6)/cell. These binding parameters did not change significantly during a 30 h incubation period with PMA or TNF-alpha. rANV inhibited HUVEC-mediated factor Xa formation via the extrinsic as well as the intrinsic route. Activation of factor X by the tissue factor-factor VII-factor X complex and tenase complex was inhibited with IC50 values of 43 +/- 30 nM and 33 +/- 24 nM respectively. Endothelial-cell-mediated generation of thrombin by the prothrombinase complex was inhibited by rANV with an IC50 of 16 +/- 12 nM. Preincubation of rANV with the endothelial cells did not significantly influence the IC50 values. These results show that rANV binds to the same extent to quiescent, PMA- and TNF-stimulated HUVEC, and, as a result of this binding, rANV efficiently inhibits endothelial-cell-mediated thrombin formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.